Sanofi’s Tzield Just Opened a Market That Didn’t Exist Last Week
Tzield's FDA approval for stage 3 type 1 diabetes creates a new disease-modifying therapy category for 2.1M U.S. patients...
Sanofi
Sanofi’s Venglustat Priority Review Is a Rare Disease Pricing License, Not Just a Clinical Win
FDA's 6-month priority review clock for Sanofi's venglustat in type 3 Gaucher disease—affecting fewer than 1,000 Americans—sets up one...
Sanofi’s Lunsekimig Just Made the Dupixent Succession Plan Legible
A bispecific nanobody hitting primary endpoints in both asthma and CRSwNP phase 2 trials isn't just a pipeline win...